HC Wainwright & Co. Reiterates Neutral on Paratek Pharmaceuticals, Maintains $2.15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce has reiterated a Neutral rating on Paratek Pharmaceuticals (NASDAQ:PRTK) and maintained a price target of $2.15.
August 07, 2023 | 10:57 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has reiterated a Neutral rating on Paratek Pharmaceuticals, maintaining a price target of $2.15.
The reiteration of a Neutral rating by HC Wainwright & Co. indicates that they do not expect significant price movement in the short term. The maintained price target of $2.15 also suggests that they believe the stock is fairly valued at its current price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100